BPG is committed to discovery and dissemination of knowledge
Prospective Study
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Mar 9, 2026; 15(1): 113478
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.113478
Neonatal cholestasis is associated with cytochrome P450 1A2 detoxification defect: A single center pilot study
Magd A Kotb, Manal M Wilson, Amani N Shafik, Noura A Ahmed, Veronia F Fahim, Nabil A Lotfi, Yasmin MR Eissawy
Magd A Kotb, Department of Pediatrics and Pediatric Hepatology, Faculty of Medicine, Cairo University, Cairo 4240310, Egypt
Manal M Wilson, Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo 12613, Egypt
Amani N Shafik, Veronia F Fahim, Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Cairo 11956, Egypt
Noura A Ahmed, Department of Pediatrics, Medical Insurance Hospital, Suez 43511, Egypt
Nabil A Lotfi, House Officer, Faculty of Medicine, Cairo University, Cairo 4240310, Egypt
Yasmin MR Eissawy, Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo 12613, Egypt
Author contributions: Kotb MA conceived the project; Kotb MA, Wilson MM, and Eissawy YMR supervised the work; Kotb MA, Wilson MM, and Ahmed NA performed clinical/Laboratory work; Kotb MA, Wilson MM, Shafik AN, Ahmed NA, Fahim VF, Lotfi NA, and Eissawy YMR analyzed data, conducted literature review, and drafted and appraised the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Research and Higher Education of Faculty of Medicine, Cairo University, approval No. MS-487-2021.
Informed consent statement: All study participants, or their legal guardians, provided informed written consent before enrollment in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Veronia F Fahim, PhD, Lecturer, Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Kasr El Ainy St., Kasr-Alainy, El Manial, Cairo 11956, Egypt. veronia.fawzy@kasralainy.edu.eg
Received: August 27, 2025
Revised: September 28, 2025
Accepted: December 15, 2025
Published online: March 9, 2026
Processing time: 192 Days and 0.6 Hours
Core Tip

Core Tip: This study investigated cytochrome P450 1A2 (CYP1A2) detoxification enzyme levels in neonates with confirmed biliary atresia (BA), neonatal hepatitis and age and sex matched healthy infants. Significantly low serum CYP1A2 was frequent among BA and neonatal hepatitis patients compared to the control group. The synergism of null glutathione S-transferase and low serum CYP1A2 in BA; the Kotb disease maybe an additional factor that compromises the aflatoxins detoxification with subsequent acceleration of the progressive inflammatory adhesions and obliterative cholangiopathy early in life. Reduced CYP1A2 seems to be an inherent susceptibility to hepatitis in the neonatal period and may alter drugs’ pharmacokinetics. Careful consideration to drug dosing and toxicity risk should be given.